The device was first recalled in 2022, but a new software update has now been released that addresses the issue. The FDA wanted a new recall to be issued to ensure all customers went through with the update.

"The singular message to the public is that the optimal treatment for multivessel coronary artery disease—to improve not only long-term survival but also lower your risk of complications—is coronary artery bypass surgery," one specialist said in a statement. 

Contrast-associated acute kidney injury is a significant problem in cardiology, especially among patients undergoing percutaneous coronary intervention. Can EHR-generated alerts make an impact?

Shockwave Medical's decision to acquire Neovasc is based largely on the potential of the Neovasc Reducer System, a solution designed to treat the symptoms of refractory angina by altering a patient's blood flow.

The device, which gained CE mark approval in Europe in May 2021, features a new-look fabric cuff designed to keep the risk of paravalvular leak (PVL) at a minimum.

The partnership is with ScImage, a California-based healthcare technology company known for its extensive EI background.

Researchers evaluated if two recently developed risk scores can anticipate adverse in-hospital outcomes after PCI, sharing their findings in the American Journal of Cardiology.

Clopidogrel monotherapy after just one month of DAPT was associated with promising outcomes, including a reduction in bleeding events.